Roy St John
Pulmonary Disease · Columbus, OHNPI 1558348839
Payments from drug & device makers
What this record shows
This record is dominated by travel and lodging: $4,593 of the $5,633 with a category attached, or 81.5%. 7 manufacturers reported payments, led by Chiesi USA, Inc. at 41.8% of the total. 2025 is the largest year on record at $4,332, more than ten times the $21 reported in 2021.
Across 37 payments — averaging $152.25 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Chiesi USA, Inc.$2K
- Eli Lilly$2K
- Boehringer Ingelheim International GmbH$1K
- GSK$125
- AstraZeneca$121
- Insmed, Inc.$32
- plus $21 from 1 others
Across 194 payments — averaging $10,022 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Eli Lilly$895K
- AstraZeneca$425K
- Astrazeneca AB$182K
- Pfizer$122K
- GSK$67K
- Biohaven Pharmaceutical Holding Company Ltd.$47K
- plus $206K from 10 others
What the payments were for
- Travel & lodging$4,59382%
- Food & beverage$98618%
- Education$531%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Chiesi USA, Inc. | 2 | $2,355 |
| Eli Lilly | 18 | $1,698 |
| Boehringer Ingelheim International GmbH | 12 | $1,280 |
| GSK | 1 | $125 |
| AstraZeneca | 1 | $121 |
| Insmed, Inc. | 2 | $32 |
| Merck | 1 | $21 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$5,633 in reported general payments places this provider in the 70th percentile of 571 pulmonary disease providers in Ohio.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Albuterol Sulfate HfaAlbuterol Sulfate | 14 | $441 |
Paid to pharmacies, not to this prescriber.
Other pulmonary disease in Columbus
- Christian GhattasColumbus$286K
- Alberto ReveloColumbus$202K
- James FaganColumbus$179K
- Jeffrey HorowitzColumbus$31K
- Ehab HusseinColumbus$25K
- Joseph KhabbazaAkron$655K
- Robert BaughmanCincinnati$640K
- Kristin HighlandCleveland$551K
- Bruce CorserCincinnati$502K
- Jason StieneckerLima$397K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.